At Jubilant Life Sciences Limited, we operate with the objective of sustainable growth along with an understanding of optimum utilisation of resources, facilitating creativity, innovation and resource conservation.
Capability to Handle Most Critical and Multi-Stage Operations

The Life Science Ingredients (LSI) business of Jubilant is supported by five state-of-the-art manufacturing facilities in India. We practice world class manufacturing concepts assuring our customers with unmatched quality and timely delivery of products. The facilities adhere to stringent safety and quality standards while following environmental friendly sustainable practices. Strategy of ‘Driving sustainable manufacturing in the dynamic business environment’ and ‘Zero tolerance to any non-compliance’ has been the core focus of Jubilant. Following the approach of triple bottom line (Environment, Economic and Social) and adopting the same as a part of the overall Company strategy, Jubilant has marched ahead towards sustainability and has recieved approval for the coveted Responsible Care Logo usage approval for Corporate Office at Noida, Uttar Pradesh, India and plant at Gajraula, Uttar Pradesh, India under the American Chemical Council’s (ACC) Responsible Care® program. Dedicated EHS teams at the Corporate Office and manufacturing facilities effectively manage health, safety and the environmental aspects of the organisation. We maintain high and uniform quality standards across our facilities.

Our continuous emphasis on compliance to regulations, GMP (Good Manufacturing Practices) and continuous improvement are key drivers for ensuring consistent quality of products. Jubilant ensures compliance by continuous assessment and review of quality systems, and compliance with industry guidelines and regulatory standards.






Global competitive edge due to integrated and efficient manufacturing operations

We believe our large scale capacity manufacturing sites in India provide us with cost advantages in terms of wages and raw materials prices as compared to many of our global competitors, as well as economies of scale. In addition, by virtue of our integrated operations, we believe that we enjoy competitive advantages in the form of cost efficiencies by producing across the value chain, thereby reducing our dependence on third parties for supply of starting materials and helps to insulate us from significant volatility in raw materials prices. The APIs from our manufacturing facility is used for Solid Dosage Formulations business. Such integration between our Solid Dosage Formulations and APIs business lines allows us to continuously improve our cost of production. Additionally, our radiopharmaceutical products are distributed through more than 50 radiopharmacies. We operate our plants in accordance with cGMP and/or other applicable requirements. We currently operate four US FDA approved manufacturing facilities in North America and two US FDA approved manufacturing facilities in India.